There are various studies with regard to COX-2 overexpression in invasive breast cancer and ductal carcinoma in situ, and the overexpression of COX-2 has been identified to be associated with aggressive histological and clinical features (19–26). Here, PTGS2 is linked to invasive breast carcinoma.